4.4 Review

Differences between adults and children: genetics and beyond

期刊

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1586/17474124.2014.950228

关键词

Crohn's disease; genetics; genome-wide association studies; IL-10R mutations; inflammatory bowel disease; ulcerative colitis; very early-onset IBD

向作者/读者索取更多资源

Clinical observations and epidemiological studies have highlighted some important differences in disease course and phenotypes between pediatric inflammatory bowel disease (IBD) and adult-onset IBD. Also from a therapeutic angle, the approach to young-onset IBD is different with a more rapid introduction of azathioprine and a high threshold for long and systemic steroid use, which may affect bone mineral density and growth. The observed clinical differences have been an area of scientific research and genetic studies have been the focus of attention. Specific candidate gene studies as well as genome-wide association studies have been performed in pediatric IBD. With the exception of very early-onset IBD occurring before the age of 2 years; no overt differences in genetic susceptibility have been identified. In contrast, very early-onset IBD seems in particular to be a genetic disease with defects in the IL10 signaling pathway being the principal example. This review aims to answer some straightforward questions arising in this topic by giving concise information.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Editorial Material Gastroenterology & Hepatology

Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn's Disease

Nathalie Van Den Berghe, Bram Verstockt, Severine Vermeire, Debby Thomas, Paul Declerck

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib

Kevin L. Winthrop, Severine Vermeire, Millie D. Long, Julian Panes, Siew C. Ng, Nicole Kulisek, Rajiv Mundayat, Nervin Lawendy, Ivana Vranic, Irene Modesto, Chinyu Su, Gil Y. Melmed

Summary: The incidence rates of herpes zoster in patients with ulcerative colitis remained stable during 7.8 years of tofacitinib exposure. Older age, lower weight, geographic region, and prior tumor necrosis factor inhibitor failure were identified as significant risk factors for herpes zoster.

INFLAMMATORY BOWEL DISEASES (2023)

Letter Gastroenterology & Hepatology

Comparative Effectiveness Research to Position Therapies in Ulcerative Colitis: How Fair Are the Comparisons?

Dahham Alsoud, Bram Verstockt, Severine Vermeire

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial

William J. Sandborn, Julian Panes, Silvio Danese, Zaineb Sharafali, Azra Hassanali, Rhian Jacob-Moffatt, Christopher Eden, Marco Daperno, John F. Valentine, David Laharie, Carolina Baia, Raja Atreya, Remo Panaccione, Grazyna Rydzewska, Humberto Aguilar, Severine Vermeire

Summary: This study compared the safety and efficacy of two doses of Etrolizumab with placebo in patients with Crohn's disease. The results showed that during the maintenance phase, Etrolizumab significantly improved clinical remission and endoscopic improvement in patients with moderately to severely active Crohn's disease compared to placebo. However, there was no significant difference in the effects of Etrolizumab and placebo on clinical remission and endoscopic improvement during the induction phase.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2023)

Review Gastroenterology & Hepatology

Advanced Imaging in Gastrointestinal Endoscopy: A Literature Review of the Current State of the Art

Pieter Sinonquel, Severine Vermeire, Frederik Maes, Raf Bisschops

Summary: This article reviews the latest developments in advanced GI endoscopy, focusing on screening, diagnosis, and surveillance of common upper and lower GI pathology. The importance of artificial intelligence in the field is emphasized, and the potential future impact of the literature is assessed.

GE PORTUGUESE JOURNAL OF GASTROENTEROLOGY (2023)

Article Gastroenterology & Hepatology

The Modified Mucosal Inflammation Noninvasive Index and Endoscopic Remission in Adults With Crohn's Disease

Dotan Yogev, Bram Verstockt, Axel Dignass, Gili Focht, Ohad Atia, Iris Dotan, Severine Vermeire, Dan Turner

Summary: Evaluation of the modified version of the Mucosal Inflammation Noninvasive Index in adult Crohn's disease.

INFLAMMATORY BOWEL DISEASES (2023)

Article Gastroenterology & Hepatology

Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program

Gary R. Lichtenstein, Brian Bressler, Carlos Francisconi, Severine Vermeire, Nervin Lawendy, Leonardo Salese, Gosford Sawyerr, Hongjiong Shi, Chinyu Su, Donna T. Judd, Thomas Jones, Edward V. Loftus

Summary: Age is considered a risk factor for adverse events in the tofacitinib ulcerative colitis clinical program, with older individuals potentially having a higher risk of herpes zoster, malignancies (excluding nonmelanoma skin cancer), and nonmelanoma skin cancer compared to younger patients.

INFLAMMATORY BOWEL DISEASES (2023)

Article Biochemistry & Molecular Biology

High Acetate Concentration Protects Intestinal Barrier and Exerts Anti-Inflammatory Effects in Organoid-Derived Epithelial Monolayer Cultures from Patients with Ulcerative Colitis

Sara Deleu, Kaline Arnauts, Lowie Deprez, Kathleen Machiels, Marc Ferrante, Geert R. B. Huys, Johan M. M. Thevelein, Jeroen Raes, Severine Vermeire

Summary: Short-chain fatty acids and their bacterial producers are gaining increasing attention in inflammatory bowel diseases. Acetate, although less studied compared to butyrate, shows potential in being less toxic to epithelial cells, stimulating butyrate-producing bacteria, and having anti-inflammatory and barrier-protective properties. In a study using organoid-based monolayer cultures from ulcerative colitis patients, high acetate concentrations were found to improve epithelial resistance, decrease pro-inflammatory markers, and enhance barrier gene expression. These findings suggest that acetate may offer a promising approach for managing barrier defects and inflammation in IBD.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Gastroenterology & Hepatology

A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases

Wannee Kantasiripitak, Sebastian G. Wicha, Debby Thomas, Ilse Hoffman, Marc Ferrante, Severine Vermeire, Karen van Hoeve, Erwin Dreesen

Summary: The study aimed to develop a multi-model model-based software tool for guiding personalized infliximab induction treatment in pediatric inflammatory bowel disease patients. The study found that using the tool for individualized dosing improved the chances for children to achieve deep remission at 6 months.

JOURNAL OF CROHNS & COLITIS (2023)

Article Gastroenterology & Hepatology

The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease

Loris Riccardo Lopetuso, Sara Deleu, Lihi Godny, Valentina Petito, Pierluigi Puca, Federica Facciotti, Harry Sokol, Gianluca Ianiro, Luca Masucci, Maria Abreu, Iris Dotan, Samuel Paul Costello, Ailsa Hart, Tariq H. Iqbal, Sudarshan Paramsothy, Maurizio Sanguinetti, Silvio Danese, Herbert Tilg, Fabio Cominelli, Theresa T. Pizarro, Alessandro Armuzzi, Giovanni Cammarota, Antonio Gasbarrini, Severine Vermeire, Franco Scaldaferri

Summary: An international panel of experts has generated evidence-based guidelines for the evaluation and management of inflammatory bowel disease (IBD) using faecal microbiota transplantation (FMT). The guidelines provide specific statements and recommendations to promote FMT as a recognized strategy for the treatment of IBD.
Article Gastroenterology & Hepatology

Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trial

Julian Panes, Severine R. Vermeire, Geert D'Haens, Silvio Danese, Fernando Magro, Maciej Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Ivana R. Bravata, Daniel Gaya, Laurent Peyrin-Biroulet, Axel Dignass

Summary: This study compared two treatment strategies for Crohn's disease patients and found that regardless of whether the treatment was "treat-to-target" or "standard of care", ustekinumab was effective in improving the health-related quality of life and work productivity of patients over a 2-year follow-up period.

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2023)

Article Gastroenterology & Hepatology

Appearance of the Bowel and Mesentery During Surgery Is Not Predictive of Postoperative Recurrence After Ileocecal Resection for Crohn's Disease: A Prospective Monocentric Study

Gabriele Bislenghi, Julie Van Den Bossch, Steffen Fieuws, Albert Wolthuis, Marc Ferrante, Gert de Hertogh, Severine Vermeire, Andre D'Hoore

Summary: The macroscopic appearance of the bowel and associated mesentery during surgery does not appear to be predictive of postoperative recurrence after ileocecal resection for Crohn's disease. Prospective studies investigating risk factors for Crohn's disease recurrence after surgery are scarce.

INFLAMMATORY BOWEL DISEASES (2023)

Article Gastroenterology & Hepatology

Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension

Silvio Danese, Remo Panaccione, Maria T. Abreu, David T. Rubin, Subrata Ghosh, Axel Dignass, Anita Afzali, Douglas C. Wolf, Michael Chiorean, Severine Vermeire, Anjali Jain, Lorna Charles, Garrett Lawlor, Mark T. Osterman, Hsiuanlin Wu, James B. Canavan, Annkatrin Petersen, Jean-Frederic Colombel, Miguel Regueiro

Summary: This interim analysis examines the efficacy and safety of ozanimod treatment in patients with ulcerative colitis over a period of approximately 3 years. The results show that a high percentage of patients maintain clinical and mucosal efficacy during the treatment. No new safety concerns arise from long-term use of ozanimod.

JOURNAL OF CROHNS & COLITIS (2023)

Article Gastroenterology & Hepatology

Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST

Laurent Peyrin-Biroulet, Severine Vermeire, Geert D'Haens, Julian Panes, Axel Dignass, Fernando Magro, Maciej Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Ivana Bravata, Frederic Lavie, Marco Daperno, Milan Lukas, Alessandro Armuzzi, Mark Loewenberg, Daniel R. Gaya, Silvio Danese

Summary: The STARDUST LTE study is the first interventional study to investigate the efficacy of ustekinumab in Crohn's disease. The study showed that flexible, algorithm-driven dose adjustment, including dose reduction, preserved clinical and endoscopic outcomes for up to 104 weeks.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Article Gastroenterology & Hepatology

Early Versus Late Use of Vedolizumab in Ulcerative Colitis: Clinical, Endoscopic, and Histological Outcomes

Severine Vermeire, Jurij Hanzel, Mark Lowenberg, Marc Ferrante, Peter Bossuyt, Frank Hoentjen, Denis Franchimont, Karoly Palatka, Harald Peeters, Aart Mookhoek, Gert de Hertogh, Tamas Molnar, Wouter van Moerkercke, Triana Lobaton, Esme Clasquin, Melanie S. Hulshoff, Filip Baert, Geert D'Haens

Summary: This study explored the differential efficacy of vedolizumab in early and late ulcerative colitis and evaluated clinical, endoscopic, and histological outcomes. The results showed no significant differences between early and late UC in terms of clinical, endoscopic, and histological improvement.

JOURNAL OF CROHNS & COLITIS (2023)

暂无数据